SAN DIEGO, March 12, 2015 /PRNewswire/ -- ResMed (NYSE:
RMD) today announced data from two studies about sleep-disordered
breathing (SDB) in chronic heart failure will be presented at the
64th Annual Scientific Sessions of the American College
of Cardiology, from March
14th through 16th.
"The data we are presenting are important because they point
toward a connection between breathing disorders in sleep, like
sleep apnea, and chronic heart failure," said ResMed Chief Medical
Officer, Glenn Richards, M.D. "We
look forward to learning the results of our landmark clinical study
called SERVE-HF, that examines whether addressing sleep-disordered
breathing in people with chronic heart failure improves
survival."
Presenting two studies on sleep-disordered breathing in
patients with chronic heart failure
- Final data from nearly 7,000 patients in a German registry of
more than 10,000 patients with stable chronic heart failure showed
that SDB was present in nearly one out of two people (46 percent).
Prevalence of SDB increased rapidly with age. Other risk factors
include male gender, more severe heart failure, atrial fibrillation
and increased weight.
This data will be presented in a poster session by Olaf Oldenburg, Senior Cardiologist in the
Department of Cardiology at the Heart and Diabetes Center North
Rhine-Westphalia, Bad Oeynhausen, Germany on Monday,
March 16th from 9:45-10:30
a.m. (Session 1252, Poster 212; Prevalence and Predictors of
Sleep-Disordered Breathing in Patients with Stable Chronic Heart
Failure: Final data of the SchlaHF Registry; Poster Hall
B1)
- Data from an American study suggest that treatment of SDB may
reduce hospital admission rates in patients with chronic heart
failure. Patients compliant with positive airway pressure (PAP)
therapy had significantly reduced hospital visits in the 6 months
after starting therapy compared to the 6 months before therapy. A
comparable group who were not compliant with PAP therapy had no
change in frequency of hospital visits.
This data will be presented in a poster session by Dr. Sunil Sharma, Associate Professor in the
Department of Medicine at Thomas Jefferson
University on Saturday, March
14th from 3:45-4:30
p.m. (Session 1145, Poster 192; Treatment Of Sleep
Disordered Breathing In Patients Admitted For Decompensated Heart
Failure Reduces 6 Months Hospital Visits, Poster Hall B1)
About Sleep-Disordered Breathing
Sleep-disordered
breathing encompasses a spectrum of breathing problems during
sleep. The two most common types of sleep apnea, a condition that
results in repetitive pauses in breathing during sleep, are
obstructive sleep apnea and central sleep apnea. In either
situation, lack of oxygen causes the person to wake up to catch
their breath and start breathing again, interrupting continuous
sleep. This may occur multiple times in an hour.
Sleep-disordered breathing is found more commonly in patients
with heart failure than it is in the general population, and people
with heart failure often report poor sleep as a symptom.
About SERVE-HF
SERVE-HF is a large randomized
controlled trial that will assess for the first time whether
treatment of predominantly central sleep apnea, with ResMed's
Minute Ventilation-targeted Adaptive Servo-Ventilation (MV-ASV)
therapy can reduce mortality and morbidity in patients with chronic
heart failure who are receiving optimized medical therapy.
About ResMed
ResMed changes lives by developing,
manufacturing and distributing medical equipment for treating,
diagnosing, and managing sleep-disordered breathing, COPD, and
other chronic diseases. We develop innovative products and
solutions to improve the health and quality of life of those who
suffer from these conditions, and we work to raise awareness of the
potentially serious health consequences of untreated
sleep-disordered breathing. For more information on ResMed, visit
www.resmed.com.
Contacts:
|
|
For News
Media
|
For
Investors
|
Alison
Graves
|
Agnes Lee
|
Director, Corporate
Communications
|
Senior Director,
Investor Relations
|
O:
858-836-6789
|
O:
858-836-5971
|
news@resmed.com
|
investorrelations@resmed.com
|
Logo -
http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a